IN2014DN09445A - - Google Patents
Info
- Publication number
- IN2014DN09445A IN2014DN09445A IN9445DEN2014A IN2014DN09445A IN 2014DN09445 A IN2014DN09445 A IN 2014DN09445A IN 9445DEN2014 A IN9445DEN2014 A IN 9445DEN2014A IN 2014DN09445 A IN2014DN09445 A IN 2014DN09445A
- Authority
- IN
- India
- Prior art keywords
- protein complexes
- viral proteins
- engineered viral
- vaccine
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- AIDS & HIV (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261644830P | 2012-05-09 | 2012-05-09 | |
| PCT/US2013/040228 WO2013169961A1 (en) | 2012-05-09 | 2013-05-09 | Conformationally specific viral immunogens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN09445A true IN2014DN09445A (ko) | 2015-07-17 |
Family
ID=49548782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN9445DEN2014 IN2014DN09445A (ko) | 2012-05-09 | 2013-05-09 |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US20130302366A1 (ko) |
| EP (2) | EP2846828B1 (ko) |
| JP (4) | JP2015518819A (ko) |
| AU (5) | AU2013259548A1 (ko) |
| CA (1) | CA2873048C (ko) |
| IN (1) | IN2014DN09445A (ko) |
| WO (1) | WO2013169961A1 (ko) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6685903B2 (ja) * | 2013-07-25 | 2020-04-22 | アバター・メディカル・エルエルシー | 立体構造的に安定化されたｒｓｖ融合前ｆタンパク質 |
| EP3027640B1 (en) | 2013-08-03 | 2018-03-07 | Avatar Medical, LLC | Influenza hemagglutinin proteins and methods of use thereof |
| CA3072293A1 (en) | 2017-08-07 | 2019-02-14 | Avatar Medical, Llc | Conformationally stabilized rsv pre-fusion f proteins |
| WO2019178521A1 (en) | 2018-03-16 | 2019-09-19 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Compositions and methods for vaccination against respiratory syncitial virus infection |
| IL298161A (en) * | 2020-05-12 | 2023-01-01 | Univ California | Single-site antibody constructs neutralize sars-cov2 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7311920B1 (en) * | 1999-10-08 | 2007-12-25 | University Of Maryland Biotechnology Institute | Virus coat protein/receptor chimeras and methods of use |
| WO2001026681A2 (en) | 1999-10-13 | 2001-04-19 | Chiron Corporation | Method of obtaining cellular immune responses from proteins |
| AU1207301A (en) * | 1999-10-15 | 2001-04-30 | Avatar Medical, Llc | Stabilized proteins |
| US6465425B1 (en) | 2000-02-10 | 2002-10-15 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins |
| US7179468B1 (en) * | 2000-06-08 | 2007-02-20 | Cornell Research Foundation, Inc. | Antigen for developing neutralizing antibodies to human immunodeficiency virus |
| WO2003052122A2 (en) | 2001-12-17 | 2003-06-26 | The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services | Gp41 inhibitor |
| US20080206264A1 (en) | 2003-02-04 | 2008-08-28 | New York University | Constrained Hiv V3 Loop Peptides as Novel Immunogens and Receptor Antagonists |
| US20050054572A1 (en) * | 2003-07-03 | 2005-03-10 | Marshall Christopher P. | Methods for obtaining molecules with reduced immunogenicity |
| CA2567030C (en) * | 2004-06-01 | 2015-10-06 | Elisabetta Bianchi | Stable peptide mimetic of hiv gp41 fusion intermediate |
| US20110076298A1 (en) * | 2006-06-19 | 2011-03-31 | Olson William C | Soluble stabilized trimeric hiv env proteins and uses thereof |
| CN105566450A (zh) * | 2007-07-27 | 2016-05-11 | 伊玛提克斯生物技术有限公司 | 免疫疗法的新型免疫抗原表位 |
| MX2010001684A (es) | 2007-08-15 | 2010-04-21 | Amunix Inc | Composiciones y metodos para modificar propiedades de polipeptidos biologicamente activos. |
| US20090246191A1 (en) * | 2007-10-11 | 2009-10-01 | University Of Tennessee Research Foundation | Preparation of Purified Covalently Cross-linked Abeta Oligomers and Uses Thereof |
| LT3335728T (lt) * | 2008-10-10 | 2020-03-10 | Children`S Medical Center Corporation | Biocheminiu požiūriu stabilizuota živ-1 env trimero vakcina |
| US20110123556A1 (en) | 2009-11-24 | 2011-05-26 | Sanjay Phogat | Immunogen prioritization for vaccine design |
| WO2011146120A2 (en) | 2010-05-18 | 2011-11-24 | Marshall Christopher P | Assay for identifying antigens that activate b cell receptors comprising neutralizing antibodies |
| US20130149336A1 (en) * | 2011-10-27 | 2013-06-13 | Brian L. Hjelle | Methods for Screening Viral Like Particles and Identifying Neutralizing Epitopes and Related Vaccines, Constructs, and Libraries |
| CN104471064B (zh) | 2012-01-20 | 2018-11-02 | 中华人民共和国香港特别行政区政府 | 副粘病毒及其用途 |
-
2013
- 2013-05-08 US US13/890,226 patent/US20130302366A1/en not_active Abandoned
- 2013-05-09 WO PCT/US2013/040228 patent/WO2013169961A1/en active Application Filing
- 2013-05-09 JP JP2015511675A patent/JP2015518819A/ja active Pending
- 2013-05-09 CA CA2873048A patent/CA2873048C/en active Active
- 2013-05-09 US US13/890,465 patent/US20130317205A1/en not_active Abandoned
- 2013-05-09 IN IN9445DEN2014 patent/IN2014DN09445A/en unknown
- 2013-05-09 EP EP13787969.8A patent/EP2846828B1/en active Active
- 2013-05-09 EP EP18200812.8A patent/EP3483174A1/en active Pending
- 2013-05-09 AU AU2013259548A patent/AU2013259548A1/en not_active Abandoned
-
2017
- 2017-02-03 US US15/424,107 patent/US10155023B2/en active Active
-
2018
- 2018-01-22 AU AU2018200502A patent/AU2018200502B2/en active Active
- 2018-05-02 JP JP2018088600A patent/JP6692853B2/ja active Active
- 2018-12-08 US US16/214,074 patent/US20190105368A1/en not_active Abandoned
-
2019
- 2019-08-16 AU AU2019216695A patent/AU2019216695A1/en not_active Abandoned
-
2020
- 2020-04-15 JP JP2020073065A patent/JP2020125323A/ja active Pending
- 2020-11-30 US US17/107,067 patent/US11752191B2/en active Active
-
2021
- 2021-06-21 AU AU2021204169A patent/AU2021204169B2/en active Active
-
2022
- 2022-08-12 JP JP2022128985A patent/JP7472209B2/ja active Active
-
2024
- 2024-02-22 AU AU2024201200A patent/AU2024201200A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20210322512A1 (en) | 2021-10-21 |
| WO2013169961A1 (en) | 2013-11-14 |
| AU2018200502B2 (en) | 2019-10-03 |
| EP2846828B1 (en) | 2018-11-21 |
| JP6692853B2 (ja) | 2020-05-13 |
| JP7472209B2 (ja) | 2024-04-22 |
| EP3483174A1 (en) | 2019-05-15 |
| US20190105368A1 (en) | 2019-04-11 |
| JP2015518819A (ja) | 2015-07-06 |
| AU2018200502A1 (en) | 2018-02-15 |
| US20130302366A1 (en) | 2013-11-14 |
| CA2873048A1 (en) | 2013-11-14 |
| AU2013259548A1 (en) | 2014-11-27 |
| AU2019216695A1 (en) | 2019-09-05 |
| US11752191B2 (en) | 2023-09-12 |
| US20130317205A1 (en) | 2013-11-28 |
| AU2021204169A1 (en) | 2021-07-15 |
| AU2024201200A1 (en) | 2024-03-14 |
| JP2018150330A (ja) | 2018-09-27 |
| JP2020125323A (ja) | 2020-08-20 |
| US10155023B2 (en) | 2018-12-18 |
| JP2022163180A (ja) | 2022-10-25 |
| CA2873048C (en) | 2020-10-27 |
| EP2846828A4 (en) | 2015-07-01 |
| US20180117116A1 (en) | 2018-05-03 |
| AU2021204169B2 (en) | 2023-11-23 |
| EP2846828A1 (en) | 2015-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018501281A1 (en) | Human immunodeficiency virus neutralizing antibodies | |
| MX2017014908A (es) | Proteinas de union triespecificas y metodos de uso. | |
| MX2018009990A (es) | Metodos para mejorar la eficacia de una vacuna mediante la administracion de un antagonista il-4r. | |
| EA201591287A1 (ru) | Вакцины, содержащие стабилизированные тримеры оболочки вируса иммунодефицита человека, и способы их применения | |
| WO2016019134A8 (en) | Flagellin-based agents and uses including effective vaccination | |
| MX2015013235A (es) | Vacuna peptidica para prevencion e inmunoterapia de la demencia tipo alzheimer. | |
| WO2013106834A3 (en) | Immunogenic wt-1 peptides and methods of use thereof | |
| MX2015008847A (es) | Composiciones inmunogenicas de virus de influenza y usos de las mismas. | |
| WO2013054199A3 (en) | Cmv antigens and uses thereof | |
| EA202090699A3 (ru) | Композиции, содержащие буфер, вакцины, которые содержат композиции, содержащие буфер, и пути их применения | |
| EA201391515A1 (ru) | Инактивированная вакцина вируса денге | |
| WO2015052543A3 (en) | Malaria vaccination | |
| WO2014160747A3 (en) | Compositions and methods for the treatment or prevention of human immunodeficiency virus infection | |
| PH12015501716B1 (en) | Anti-mycoplasma spp. subunit vaccine | |
| IN2014DN09445A (ko) | ||
| MX2019005102A (es) | Poxvirus quimericos sinteticos. | |
| MX2017008406A (es) | Conjugados de aminoacidos y peptidos y sus usos. | |
| MX2022002635A (es) | Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso. | |
| TW201613977A (en) | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use | |
| TN2018000180A1 (en) | Polypeptides inhibiting cd40l | |
| MX2015013304A (es) | Vacunas de nucleoproteina de la influenza. | |
| MX2019007924A (es) | Vacunas contra la influenza. | |
| WO2016049522A3 (en) | Compositions comprising ch505 envelopes, and trimers | |
| WO2015086354A3 (en) | Novel promiscuous hpv16-derived t helper epitopes for immunotherapy | |
| MX358507B (es) | Antigenos vacunales quimericos contra el virus de la hepatitis c. |